RecruitingPhase 2NCT03593317
Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
Studying Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hospices Civils de Lyon
- Principal Investigator
- Philippe Chevalier, MD, PhDHospices Civils de Lyon
- Intervention
- Spironolactone(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2029
Study locations (13)
- CHU Amiens Picardie, Amiens, France
- Hôpital Cardiologique Louis Pradel, Bron, France
- Hôpital Gabriel Montpied, Clermont-Ferrand, France
- CHU Dijon, Dijon, France
- Hôpital Michallon, Grenoble, France
- Hôpital de la Timone, Marseille, France
- Hôpital Arnaud de Villeneuve, Montpellier, France
- Hôpital Laennec, Nantes, France
- Groupe Hospitalo Universitaire Caremeau, Nîmes, France
- Hôpital Pitié Salpetrière, Paris, France
- Hôpital de Haut-Lévêque, Pessac, France
- Nouvel Hôpital Civil, Strasbourg, France
- Hôpital Rangueil, Toulouse, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03593317 on ClinicalTrials.govOther trials for Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06228924Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVCTenaya Therapeutics
- RECRUITINGNANCT05209776Local Inflammation in Arrhythmogenic Right Ventricular CardiomyopathyUniversity Hospital, Toulouse
- RECRUITINGNCT03049254Mayo AVC Registry and BiobankMayo Clinic
See all trials for Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant →